Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Codomol is a fixed-dose combination analgesic marketed by Omnica Laboratories, primarily in the Philippines. It consists of paracetamol (acetaminophen), a non-opioid analgesic and antipyretic, and codeine phosphate, an opioid analgesic. Paracetamol is thought to act primarily in the central nervous system by inhibiting prostaglandin synthesis through the cyclooxygenase (COX) pathway and potentially modulating the endocannabinoid system. Codeine phosphate acts as a prodrug that is metabolized to morphine, which then functions as an agonist at the mu-opioid receptors to alter the perception of and emotional response to pain. Codomol is indicated for the relief of mild to moderate pain where other non-opioid analgesics have proven insufficient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine phosphate + paracetamol.